Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026

Jefferies maintained a Hold rating on Mineralys Therapeutics, Inc. (MLYS) on March 13, 2026. This MLYS analyst rating included a price target cut to $30, cited in the Jefferies note. The StreetInsider report shows the update and a short-term market reaction. Investors should note the note also recorded a -2.75% ($-0.74) price change at the time of the bulletin. We use Meyka AI data to frame the implications for holders and traders.

MLYS analyst rating: Jefferies maintains Hold on March 13, 2026

Jefferies kept Mineralys Therapeutics, Inc. (MLYS) at Hold on March 13, 2026. The firm signaled caution by lowering the price target while keeping the rating the same. This action is a maintained rating, not an upgrade or downgrade, and it reflects a measured view on near-term catalysts.

Jefferies price target lowered to $30

Jefferies cut the Mineralys price target to $30 while maintaining the Hold rating. The StreetInsider note documents the change and Jefferies’ rationale, which emphasizes valuation pressure and timing of clinical catalysts. Read the Jefferies brief on StreetInsider for full details source.

Market reaction and stock performance after the update

The Jefferies note coincided with a -2.75% ($-0.74) move recorded in the update feed. Mineralys Therapeutics, Inc. has a market cap of $1,736,288,495 and short-term flows can amplify price moves. For context on broader analyst activity in this window, see recent coverage trends on Investing.com source.

What a maintained Hold rating means for investors

A maintained Hold signals that Jefferies sees limited near-term upside versus risk. Hold means investors should expect flat to mixed returns absent new data or catalysts. Traders may use the rating with the revised $30 price target to size positions, while long-term holders should compare this view with company milestones.

Analyst coverage history and perspective on Mineralys Therapeutics, Inc.

Analyst coverage for Mineralys has been selective, with Jefferies the recent active voice on March 13, 2026. Historical notes show periodic target revisions tied to clinical readouts and licensing progress. The current maintained Hold follows prior mixed analyst stances and limited firm followings, so investor attention should weigh scarce coverage against company fundamentals.

Meyka grade, outlook and next steps for MLYS investors

Meyka AI rates MLYS with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is proprietary and not a recommendation. Investors should monitor clinical updates, partnerships, and any new analyst notes for re-ratings.

Final Thoughts

Jefferies’ March 13, 2026 note kept Mineralys Therapeutics, Inc. (MLYS) at Hold and lowered the price target to $30, a move that tempered near-term sentiment. The kept rating suggests Jefferies expects limited upside without fresh catalysts. The market reacted with a -2.75% ($-0.74) price shift at the time of the report. Investors should treat this MLYS analyst rating as a signal to reassess position sizing and catalyst timelines. Combine analyst notes with the Meyka AI grade of B and fundamental checks before adjusting holdings. For active traders, the maintained Hold plus cut target can inform short-term risk management. Long-term investors should watch for clinical milestones that could prompt future upgrades or downgrades.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.